Neolpharma Group is formed by Mexican companies concerned with healthcare. With more than 40 years of experience in production of controlled and uncontrolled substances in different presentations, we offer our customers medicines of the highest quality produced with cutting-edge technology and provide integral solutions. All of this thanks to our highly qualified staff.
More than 15 years ago, we started a vertical integration process of various business units, which are dedicated to research and development, production, sales and distribution. This was done in order to offer patients drugs with proven efficacy, safety and the best cost-benefit ratio.
Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
India’s National Chemical Laboratory (NCL), one of the most well-established labs in the wider Council of Scientific and Industrial Research (CSIR) network, has made some major contributions to improving the…
PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient…
Shailesh Siroya explains the rationale behind Bal Pharma’s strategic focus on niche products within the API segment, avoiding the broader, more competitive commodity markets and enabling it to establish a…
Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation.…
After achieving the highest sales figures in the affiliate’s history in 2023, general manager of Teva Pharmaceuticals Portugal Marta Gonzalez Casal outlines the restructuring efforts that have taken place in…
Mohal Sarabhai, managing director of Ambalal Sarabhai Enterprises Limited (ASE) on transforming his family’s failing century-old business and creating new companies beneath the ASE Holdings umbrella, including a joint venture…
The Portuguese Association of Hospital Pharmacists (APFH) is dedicated to the education and training of over 1000 hospital pharmacists; essential members of the multidisciplinary teams needed to tackle serious illnesses…
Dr Arunish Chawla details the policy strategies underlying the explosive prospected growth of India’s pharmaceutical sector to USD 120-150 billion by 2030, including rigorous adherence to international quality standards. Highlighting…
See our Cookie Privacy Policy Here
